Can cilastatin shield kidneys during ovarian cancer surgery?

NCT ID NCT07229040

Recruiting now Disease control Sponsor: Hospital General Universitario Gregorio Marañon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two drugs, cilastatin and thiosulfate, for protecting the kidneys in women with ovarian cancer who undergo surgery with heated chemotherapy. About 90 patients will be randomly assigned to receive one of the drugs during the procedure. The main goal is to see which drug better prevents kidney injury in the week after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cilastatin
What this could lead to: If cilastatin works better, it could offer a safer way to protect kidneys during heated chemotherapy for ovarian cancer.
What could go wrong: This is a small phase 2 trial, so results may not apply broadly. Also, both drugs have risks, and the study is only comparing kidney protection, not curing the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY DEBULKING SURGERY FOR OVARIAN CANCER

Contacts and locations

Locations

Hodpsital General Universitario Gregorio Marañón
RECRUITING

Madrid, Madrid, 28007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.